Californian company claims 'advantages over other vaccines and therapies' for COVID-19

10 August 2020
ligandal_large

Ligandal, a genetic medicine company that uses nanotechnology to develop targeted and personalized therapies, has announced the positive results of laboratory studies that demonstrate the effectiveness of its synthetic peptide, SARS-BLOCK, as a combination treatment and vaccine to COVID-19.

The experiments, in conjunction with the Stroud Lab, University of California San Francisco, demonstrate that SARS-BLOCK halts infection of SARS-CoV-2.

Addresses virus itself

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology